# US 12,180,216 B2 · Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABAA receptor agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,216 B2
- Document ID: US12180216B2
- Status: Granted
- Kind: B2
- Application number: 18/363,933
- Filed: 2023-08-02
- Published: 2024-03-14
- Granted: 2024-12-31
- Earliest claimed: 2016-03-18
- Assignees: UWM Research Foundation, Inc.
- Applicants: UWM Research Foundation, Inc.; Centre for Addiction and Mental Health; University of Belgrade—Faculty of Pharmacy
- Inventors: James M. Cook; Guanguan Li; Michael Ming-Jin Poe; Miroslav M. Savic; Etienne Sibille
- Web page: https://patentgrep.com/patent/US12180216B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07F 7/0812: {comprising a heterocyclic ring}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Provided herein are alpha5-containing GABAA receptor agonists and pharmaceutical compositions and methods of treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders using them.

## Claims

### Claim 1

A method of treating cognitive and/or mood symptoms in a subject in need thereof, comprising administering a compound having a structure of
or a pharmaceutically acceptable salt thereof, to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound is

### Claim 5 (depends on 1)

The method of claim 1, wherein the cognitive and/or mood symptoms result from depression, epilepsy, post-traumatic stress disorder (PTSD), or a neurological disorder.

### Claim 6 (depends on 5)

The method of claim 5, wherein the neurological disorder is a neuropsychiatric disorder or a neurodegenerative disorder.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neuropsychiatric disorder is major depressive disorder, bipolar disorder, or schizophrenia.

### Claim 8 (depends on 6)

The method of claim 6, wherein the neurodegenerative disorder is Alzheimer's disease.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is
and the cognitive and/or mood symptoms result from major depression, depressive disorder, bipolar disorder, schizophrenia, Alzheimer's disease, epilepsy, or PTSD.

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound is
and the cognitive and/or mood symptoms result from depression, major depressive disorder, bipolar disorder, schizophrenia, Alzheimer's disease, epilepsy, or PTSD.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound is
and the cognitive and/or mood symptoms result from depression, major depressive disorder, bipolar disorder, schizophrenia, Alzheimer's disease, epilepsy, or PTSD.

### Claim 12

A compound having a structure
or a pharmaceutically acceptable salt thereof.